top of page
Trevarx Biomedical is pioneering a new oncology paradigm through its novel small molecule radiopharmaceutical platforms. With two complementary programs — [211At]PTT (a therapeutic alpha-emitter) and [18F]FTT (a PET imaging biomarker) — Trevarx is enabling tumor-specific treatment and precision diagnostics for PARP-expressing cancers. With over $20M in prior research investment and exclusive IP licenses, Trevarx is advancing first-in-human trials in ovarian cancer and a multicenter Phase 2 study in breast cancer.

Lead Program & Pipeline

  • [211At]PTT: Alpha-emitting small molecule therapeutic targeting PARP-1 in solid tumors

    • Preclinical phase; preparing for Phase 1 in ovarian cancer

    • Strong early efficacy shown in preclinical neuroblastoma models

  • [18F]FTT: Companion PET imaging biomarker for PARP-1 tumor expression

    • In Phase 2 multicenter breast cancer trial led by MD Anderson, Penn, and Wash U

    • Over 296 patients imaged with consistent results and no adverse events

  • Pipeline expansion targeting prostate, breast, and additional PARP-expressing cancers

Technology Differentiators

  • First-ever alpha-emitting therapy (using Astatine-211) designed for subcellular DNA targeting via PARP-1

  • Dual diagnostic-therapeutic approach enables tumor-specific treatment selection

  • Biomarker product enables real-time identification of PARP-1 expression, addressing a major limitation of current genomic assays

  • Extensive validation through academic collaboration and $19M+ in non-dilutive NIH and DOD grants

Stage & Investment

  • Stage:

    • [18F]FTT: Phase 2, planning for pre-NDA meeting

    • [211At]PTT: Preclinical, Phase 1 IND in preparation

  • Funding Raised: $1.15M pre-seed + $5M non-dilutive

  • IP:

    • [18F]FTT: Issued patents through 2035 (licensed from WUSTL)

    • [211At]PTT: Patents from Penn, pending therapeutic method coverage

  • Collaborators: MD Anderson, University of Pennsylvania, WUSTL, University of Washington

What's Next

  • Complete [18F]FTT Phase 2 trial and initiate pre-NDA discussions with FDA

  • Secure strategic licensing partner for [18F]FTT in North America and Europe

  • Finalize IND-enabling work for [211At]PTT and submit Phase 1 IND

  • Apply for $2M SBIR Phase II and raise Seed/Series A to fund PTT clinical trials

  • Expand scientific infrastructure and business development capacity for commercialization

Leadership

Jean-Cho.jpg
Jean Cho, MBA
CEO & Co-founder
mach_robert.jpg
Robert Mach, PhD
Co-founder
bottom of page